Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
IDEAYA Biosciences ( (IDYA) ) has provided an announcement.
On January 11, 2026, IDEAYA Biosciences outlined its 2026 corporate objectives, highlighting plans to advance four registrational trials, including darovasertib across the uveal melanoma disease continuum and IDE849 as a monotherapy in neuroendocrine cancers, with key clinical milestones expected throughout the year. The company aims to deliver topline progression-free survival data in the first quarter of 2026 from the Phase 2/3 OptimUM-02 trial of darovasertib plus crizotinib in first-line HLA*A2‑negative metastatic uveal melanoma, complete or initiate additional Phase 3 and Phase 2 trials across metastatic, neoadjuvant, and adjuvant settings, and progress multiple ADC and MTAP-pathway programs into early-stage clinical studies, while emphasizing that its approximately $1.1 billion in cash and securities as of September 30, 2025 is expected to fund operations into 2030 and support global commercial readiness efforts with Servier for darovasertib.
The most recent analyst rating on (IDYA) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.
Spark’s Take on IDYA Stock
According to Spark, TipRanks’ AI Analyst, IDYA is a Neutral.
IDEAYA Biosciences’ overall stock score reflects significant financial challenges and valuation concerns, primarily due to ongoing losses and a negative P/E ratio. The technical analysis shows some positive trends, but momentum is limited. The termination of the GSK collaboration adds uncertainty, although promising clinical data provides some optimism.
To see Spark’s full report on IDYA stock, click here.
More about IDEAYA Biosciences
IDEAYA Biosciences is a clinical-stage oncology company focused on precision medicine and synthetic lethality, developing targeted small molecules and antibody-drug conjugates for genetically defined cancers. Its pipeline includes darovasertib for uveal melanoma, IDE849 and other ADC programs for DLL3- and B7H3-expressing tumors, and multiple MTAP-pathway agents such as IDE397 and IDE892, with a global commercial partnership for darovasertib with Servier and a strong cash position supporting long-term development.
Average Trading Volume: 1,046,757
Technical Sentiment Signal: Buy
Current Market Cap: $3.19B
For an in-depth examination of IDYA stock, go to TipRanks’ Overview page.